Telimaa S, Rönnberg L, Kauppila A
Department of Obstetrics and Gynecology, University of Oulu, Finland.
Gynecol Endocrinol. 1987 Dec;1(4):363-71. doi: 10.3109/09513598709082709.
To evaluate the clinical value of postoperative hormone therapy in endometriosis, 60 patients with advanced disease were randomized to receive in a double-blind study danazol (200 mg, 3 times daily), medroxyprogesterone acetate (MPA) (100 mg daily) or placebo post-operatively for 6 months. Treatment efficacy was evaluated clinically and at laparoscopy 6 months after medication. In relation to placebo, danazol and high-dose MPA treatments, which did not differ from each other in efficacy, significantly alleviated pelvic pain. In addition, the peritoneal endometriosis lesions found at 6-months laparoscopy were significantly smaller in the MPA and danazol groups than in the placebo group. Breakthrough bleeding, weight gain and acne complicated danazol treatment but only breakthrough bleeding complicated MPA treatment. These data suggest that postoperative treatment of advanced endometriosis with high-dose MPA or danazol is clinically beneficial.
为评估术后激素治疗在子宫内膜异位症中的临床价值，60例晚期疾病患者在一项双盲研究中被随机分组，术后接受达那唑（200毫克，每日3次）、醋酸甲羟孕酮（MPA）（每日100毫克）或安慰剂治疗6个月。在用药6个月后通过临床及腹腔镜检查评估治疗效果。与安慰剂相比，达那唑和高剂量MPA治疗在疗效上无差异，但均显著减轻了盆腔疼痛。此外，在6个月腹腔镜检查时发现，MPA组和达那唑组的腹膜子宫内膜异位症病灶明显小于安慰剂组。突破性出血、体重增加和痤疮是达那唑治疗的并发症，而MPA治疗仅出现突破性出血并发症。这些数据表明，用高剂量MPA或达那唑对晚期子宫内膜异位症进行术后治疗在临床上是有益的。
